Transcription of RAINBOW - jgca.jp
{{id}} {{{paragraph}}}
Example: stock market
RAINBOW - jgca.jp
RAINBOW REGARD RAINBOW ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma ( RAINBOW ): a double-blind, randomised phase 3 trial Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A, for the RAINBOW Study Group Lancet Oncol 15: 1224-1235, 2014 Eli Lilly and Company RAINBOW 27 170 III 18 4 8mg/kg, days 1, 15 28 80mg/m2, days 1, 8, 15 28 1:1 2010 12 2012 9 665 330 335 95% 95% 95% p= 5% Grade 3 41% 19 17% 7 14% 2 12% 5 9% 10 6% 3 3% 2
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicenter placebo-controlled, phase 3 trial
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: